Evogene (EVGN) Q4 2024 earnings summary

Executive summary

• 2024 revenues rose to $8.5M from $5.6M, driven by AgPlenus-Bayer collaboration and Casterra seed sales.

• Net loss narrowed to $18.1M from $26.0M, reflecting higher revenues, lower R&D, and increased financial income from warrants.

• New Chairman Nir Nimrodi appointed, emphasizing value creation, capital efficiency, and commercialization experience.

• Strategic focus on leveraging AI-driven tech engines, especially ChemPass AI, for drug discovery and life sciences.

• Expense reduction plan initiated, including a 30% headcount cut by end of Q1 2025.

Financial highlights

• Q4 2024 revenues were $1.6M, up from $0.6M in Q4 2023; full-year revenues $8.5M, up from $5.6M.

• Net loss for 2024 was $18.1M, a significant improvement from $26M in 2023; Q4 2024 net loss was $5,000, down from $7.3M in Q4 2023.

• Operating loss for 2024 was $22.2M, down from $26.5M in 2023; Q4 2024 operating loss was $4.6M, down from $7.6M.

• R&D expenses fell to $16.6M from $20.8M; Q4 R&D $3.4M vs $5.5M.

• G&A expenses rose to $7.4M from $6.1M, including $1.5M in one-time fundraising and doubtful debt costs.

• Cash and equivalents at year-end 2024 were $15.3M; Q4 2024 cash usage was $4.6M.

• 2024 financing income net was $4.2M, mainly from warrant-related accounting.

Outlook and guidance

• 2025 cash burn from operations expected at $6–7M, excluding proceeds from potential subsidiary sales.

• Continued focus on expense reduction, with headcount cut by 30% to be completed in Q1 2025.

• Strategic intent to create exit events for subsidiaries to inject funds and support core activities.

• Focus in 2025–2026 on enhancing ChemPass AI for pharma, expanding collaborations, and supporting subsidiary fundraising.

• Casterra aims to increase seed revenue in Africa and Brazil, initiate grain farming PoC trials, and develop new seed varieties.